SCHEMBL4291859

SCHEMBL4291859

CCCCCCCCCCc1ccc(CNC2CCC(C(=O)O)(C(=O)O)C2)cc1

nearest known ligand 0.52

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 8/20 0.52
S1PR3 Q99500 8/20 0.52
S1PR4 O95977 6/20 0.52
S1PR5 Q9H228 2/20 0.52
S1PR2 O95136 5/20 0.46
HAO1 Q9UJM8 1/20 0.45
SPHK1 Q9NYA1 7/20 0.45
EPHX1 P07099 1/20 0.45
EPHX2 P34913 1/20 0.45
PLK1 P53350 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4290752 1.00 S1PR1 (0.52) S1PR1S1PR3S1PR4S1PR5S1PR2
SCHEMBL4296871 1.00 S1PR1 (0.52) S1PR1S1PR3S1PR4S1PR5S1PR2
Hydrochloric Acid SCHEMBL4295936 0.99 S1PR1 (0.51) S1PR1S1PR3S1PR4S1PR5S1PR2
SCHEMBL4291433 0.94 S1PR1 (0.49) S1PR1S1PR3S1PR4S1PR5S1PR2
SCHEMBL4291363 0.93 S1PR1 (0.48) S1PR1S1PR3S1PR4S1PR5S1PR2
SCHEMBL4290855 0.93 S1PR1 (0.48) S1PR1S1PR3S1PR4S1PR5S1PR2
SCHEMBL4300316 0.92 S1PR1 (0.47) S1PR1S1PR3S1PR4S1PR5S1PR2
Hydrochloric Acid SCHEMBL4293572 0.92 S1PR1 (0.47) S1PR1S1PR3S1PR4S1PR5S1PR2
SCHEMBL4289649 0.92 S1PR1 (0.47) S1PR1S1PR3S1PR4S1PR5S1PR2
SCHEMBL4293664 0.92 S1PR1 (0.47) S1PR1S1PR3S1PR4S1PR5S1PR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090264469-A1 NOVEL DICARBOXYLIC ACID DERIVATIVES BIO-PROJET (FR) 2009-10-22 US claimed
EP-1650186-B1 Novel dicarboxylic acid derivatives BIOPROJET SOC CIV (FR) 2008-06-04 EP claimed
WO-2006043149-A9 NOVEL DICARBOXYLIC ACID DERIVATIVES BIOPROJET SOC CIV (FR) 2006-08-10 WO claimed
WO-2006043149-A2 NOVEL DICARBOXYLIC ACID DERIVATIVES BIOPROJET (FR) 2006-04-27 WO claimed
EP-1650186-A1 Novel dicarboxylic acid derivatives BIOPROJET (FR) 2006-04-26 EP claimed
US-20090264469-A1 NOVEL DICARBOXYLIC ACID DERIVATIVES BIO-PROJET (FR) 2009-10-22 US disclosed
EP-1650186-B1 Novel dicarboxylic acid derivatives BIOPROJET SOC CIV (FR) 2008-06-04 EP disclosed
WO-2006043149-A9 NOVEL DICARBOXYLIC ACID DERIVATIVES BIOPROJET SOC CIV (FR) 2006-08-10 WO disclosed
WO-2006043149-A2 NOVEL DICARBOXYLIC ACID DERIVATIVES BIOPROJET (FR) 2006-04-27 WO disclosed
EP-1650186-A1 Novel dicarboxylic acid derivatives BIOPROJET (FR) 2006-04-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264469-A1 NOVEL DICARBOXYLIC ACID DERIVATIVES S1PR2, S1PR1, S1PR5 S1PR1 2/4885S1PR3 4/4885S1PR4 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.